RxDoctor Payments Data

Lyla Veen, MD

Neurology · Coon Rapids, MNNPI 1538325345

Payments from drug & device makers

$522in general payments, 2019–2025

Across 17 payments — averaging $30.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$163
  • ZOLL Respicardia, Inc.$130
  • Itamar Medical Inc$93
  • Jazz Pharmaceuticals Inc.$37
  • Akcea Therapeutics, Inc.$18
  • Teva Pharmaceuticals USA, Inc.$15
  • plus $66 from 5 others

What the payments were for

  • Speaking & faculty fees$143%
  • Food & beverage$50997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 60th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$231,648
Medicare patients
263
Services billed
6,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin13$135,114
CopaxoneGlatiramer Acetate12$69,984
GlatopaGlatiramer Acetate11$27,060
Aimovig AutoinjectorErenumab-Aooe23$17,027
Nurtec OdtRimegepant Sulfate12$12,263
Emgality PenGalcanezumab-Gnlm18$12,118
Pregabalin111$6,283
Carbamazepine ErCarbamazepine53$6,205
DilantinPhenytoin Sodium Extended18$5,625
Carbidopa-LevodopaCarbidopa/Levodopa129$5,307
BelbucaBuprenorphine Hcl17$4,061
Gabapentin155$3,912
Levetiracetam133$3,634
Carbamazepine55$2,812
Divalproex Sodium ErDivalproex Sodium30$2,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$15$69,98412 claims
Upsher-smith Laboratories LLCTopiramate$13$1,25155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 neurology providers in Minnesota.

Other neurology in Coon Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →